Appendix 4c quarterly activity report for quarter ended june 30, 2023

New york, july 30, 2023 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended june 30, 2023.

MESO Ratings Summary

MESO Quant Ranking